Vyndamax

PreclinicalSmall molecule

Vyndamax is one of 6 small molecule programs targeting Transthyretin Amyloid Cardiomyopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transthyretin Amyloid CardiomyopathyActive, not recruiting

Transthyretin Amyloid CardiomyopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Transthyretin Amyloid Cardiomyopathy

#DrugCompanyPhaseTrials

Vyndaqel

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Approved

4 2

Attruby

NNavire Pharma Inc., a BridgeBio company

Approved

2 3

Jardiance

Boehringer Ingelheim

Approved

1 4

Onpattro

Alnylam Pharmaceuticals

Approved

—5

Wainua (autoinjector)

AstraZeneca

Phase 3

1 6

Vyndamax

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ATTR-CM1 trial

KOREAN POST-MARKETING SURVEILLANCE VYNDAMAX (REGISTERED) CAPSULES FOR THE TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

Completed· Pfizer logo

Pfizer··NCT04801329·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vyndamax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vyndamax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vyndamax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Vyndamax

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ATTR-CM1 trial

References

Drug Info

Quick Facts

Related News